AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ENDEAVOR BIOMEDICINES · Biotechnology & therapeutics

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $51,000.00 income · posted Oct 15, 2025

Lobbying activity 1

Health Issues

RESULT Act FDA Modernization

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem